Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis (Q30433673)

6 November 2017

Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis (English)

1 reference

6 November 2017

7

Craig L Slingluff

1 reference

6 November 2017

Kristin Turza

1

1 reference

6 November 2017

Lynn T Dengel

2

1 reference

6 November 2017

Rebecca C Harris

3

1 reference

6 November 2017

James W Patterson

4

1 reference

6 November 2017

Kevin White

5

1 reference

6 November 2017

William W Grosh

6

1 reference

6 November 2017

7 July 2009

1 reference

Journal of Cutaneous Pathology

6 November 2017

1 reference

6 November 2017

37

1 reference

6 November 2017

1

1 reference

6 November 2017

94-98

1 reference

Treatment of lentigo maligna with imiquimod before staged excision

6 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

The role of topical immune response modifiers in skin cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Imiquimod in the treatment of lentigo maligna

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Topical imiquimod in the treatment of metastatic melanoma to skin

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2904832

Topical imiquimod treatment of a cutaneous melanoma metastasis

26 November 2018

1 reference

12 December 2020

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

12 December 2020

Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma

1 reference

12 December 2020

Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod

1 reference

12 December 2020

Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor

1 reference

12 December 2020

Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports

1 reference

12 December 2020

Lentigo maligna successfully treated with imiquimod

1 reference

12 December 2020

10.1111/J.1600-0560.2009.01290.X

Identifiers

DOI

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

19602071

1 reference